ASCO 2023: Multi-cancer blood test shows real promise
The SYMPLIFY study is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals…
Browsing: Featured Events
ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients
While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent…
ASCO 2023: Phase 3 trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy
A phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma…
ASCO 2023: Thyroid cancer precision approaches that incorporate targeted therapies and other treatments are changing the surgeon’s role
Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as…
ASCO 2023: Immunotherapy for brain cancer metastases shows clinical benefit
In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that…
ASCO 2023: Antibody-microtubule inhibitor conjugate improves survival in women with recurrent ovarian cancer
MIRASOL, an international phase III randomised clinical trial, found that mirvetuximab soravtansine, an antibody and…
ASCO 2023: Trastuzumab deruxtecan effectively treats HER2-expressing cancers regardless of tumour location
Trastuzumab deruxtecan (marketed as Enhertu) is an effective treatment option for people with difficult-to-treat HER2-expressing…
ASCO 2023: Radiation can be safely omitted in select patients with locally advanced rectal cancer
“We’ve reached a tipping point in treating patients with rectal cancer. As we develop new…
Cancer experts, patient advocates, industry and political leaders debate the true value of oncology
Australia is riding a wave of emerging innovative and ground-breaking diagnostic technologies and cancer treatments…
AACR 2023: Treatment with immunotherapy alone produces ‘exceptional’ response rates in some melanoma patients
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic…